[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627844":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":24,"locations":34,"responsibleParty":67,"collaborators":12,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":12,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":102,"whyStopped":12,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"BioMérieux","INDUSTRY",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control arm","NO_INTERVENTION","Standard of care",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention arm","EXPERIMENTAL","SPOTFIRE R will be used as a frontline test and results obtained prior to any additional procedure and\u002For prescription performed as per standard procedure",[18],"Diagnostic Test: SPOTFIRE R",[20],{"type":21,"name":22,"description":16,"armGroupLabels":23,"otherNames":12},"DIAGNOSTIC_TEST","SPOTFIRE R",[14],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":12,"email":29},"Solenne Robert, MS","CONTACT","+33684478785","solenne.robert@biomerieux.com",{"name":31,"role":27,"phone":12,"phoneExt":32,"email":33},"Eline Malluile, Pharm D","+33624581164","eline.malluile@biomerieux.com",[35,47,57],{"facility":36,"status":12,"city":37,"state":12,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":12},"Hopital Robert Debré","Paris","75019","France","FR",{"type":42,"coordinates":43},"Point",[44,45],2.3488,48.85341,{"lat":45,"lon":44},{"facility":48,"status":12,"city":49,"state":12,"zip":12,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":56,"contacts":12},"Ippokratio - General Hospital","Thessaloniki","Greece","GR",{"type":42,"coordinates":53},[54,55],22.93493,40.64072,{"lat":55,"lon":54},{"facility":58,"status":12,"city":59,"state":12,"zip":12,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":66,"contacts":12},"Södersjukhuset Hospital","Stockholm","Sweden","SE",{"type":42,"coordinates":63},[64,65],18.06871,59.32938,{"lat":65,"lon":64},{"type":68,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100627844","clinical-assessment-of-respiratory-events-for-kids-integrating-diagnostics-and-stewardship-100627844",false,"NCT07453914","Clinical Assessment of Respiratory Events for Kids: Integrating Diagnostics and Stewardship","CARE4KIDS","Inclusion Criteria:\n\n* Children from 60 days until less than 18 years old with signs and\u002For symptoms leading to suspicion of Respiratory Tract Infection (RTI) and\u002For Influenza-Like Illness (ILI), such as fever (Temperature greater than or equal to 37.8°C), rhinorrhea, nasal obstruction, sneezing, sore throat of pharyngeal pain, difficulties in breathing and\u002For cough, tachypnea, shortness of breath, apnea, croup.\n* Children and his\u002Fher legal representative who provide their informed consent.\n* Patients willing to provide a Nasopharyngeal Swab (NPS).\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator\u002Fnurse results in significant immune dysfunction such as known primary immunodeficiency disorder, ongoing immunosuppressive therapy, known HIV infection, active or recent oncologic disease, transplant recipients and\u002For chronic use of immunomodulating agents,\n* Any condition that, in the opinion of the investigator\u002Fnurse, is related to severe patients requiring urgent referral who need to go on intensive care (such as patients who have a diagnosis of sepsis or septic shock,\n* Known pregnancy\n* Patients who refused to participate in the study and therefore declined Informed Consent Form.","ALL","60 Days","17 Years",{"count":80,"type":81},720,"ESTIMATED","INTERVENTIONAL",[84],"NA","This study, called Care4Kids, aims to improve the management of respiratory infections in children visiting emergency departments. The research will evaluate the impact of using the BIOFIRE® SPOTFIRE® R\u002FST Panel, a rapid molecular point-of-care test, compared to standard care.\n\nChildren aged 2 months to 18 years with symptoms of respiratory tract infection or flu-like illness will be enrolled. After consent, participants will be randomly assigned to one of two groups:\n\n* Intervention group: The SPOTFIRE test will be performed immediately to guide treatment decisions.\n* Control group: Patients will receive standard care without the rapid test. The study will take place in three pediatric emergency departments in France, Greece, and Sweden. Up to 720 children will participate. A follow-up phone call will be made 14 days after the visit to check recovery and satisfaction.\n\nThe goal is to see whether rapid testing improves patient outcomes, reduces unnecessary treatments, and increases caregiver satisfaction.",[87,88,89],"Respiratory Tract Infections (RTI)","Influenza-like Illness","Children",[91,92,93,94,95,96,97,98,99,100,101],"Respiratory Tract Infection","Pediatric Respiratory Disease","Viral Respiratory Infection","Bacterial Respiratory Infection","children","Pediatrics","Stewardship","Diagnostic","Multicenter Study","Point Of Care Testing","multiplex Polymerase Chain Reaction.","NOT_YET_RECRUITING","2026-03-03",{"date":105,"type":106},"2026-03-06","ACTUAL",{"date":108,"type":81},"2026-03",{"date":110,"type":81},"2026-09",{"name":5,"class":6},3]